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Abstract
Long-term opioid therapy (LTOT) is associated with increased risk for depression. It is not known if the frequency of opioid use during
LTOT is associated with new-onset depression. We used Optum’s de-identified Integrated Claims-Clinical dataset (2010-2018) to
create a cohort of 5146 patients, 18 to 80 years of age, with an encounter or claims in the year before new LTOT. New LTOT was
defined by .90-day opioid use after remaining opioid free for 6 months. Opioid use frequency during the first 90 days of LTOT was
categorized into occasional use (,50% days covered), intermittent use (50% to ,80% days covered), frequent use (80% to ,90%
days covered), and daily use ($90% days covered). Propensity scores and inverse probability of exposure weighting controlled for
confounding in models estimating risk for new-onset depression. Patients were on average 54.5 (SD 6 13.6) years of age, 55.7%
were female, 72.5% were White, and 9.5% were African American. After controlling for confounding, daily users (hazard ratio 5 1.40;
95% confidence interval: 1.14-1.73) and frequent users (hazard ratio 5 1.34; 95% confidence interval: 1.05-1.71) were significantly
more likely to develop new-onset depression compared with occasional users. This association remained after accounting for the
contribution of post-index pain diagnoses and opioid use disorder. In LTOT, risk for new depression episodes is up to 40% greater in
near-daily users compared with occasional users. Patients could reduce depression risk by avoiding opioid use on as many low pain
days as possible. Repeated screening for depression during LTOT is warranted.
Keywords: Cohort, Epidemiology, Pain, Opioid, Depression

1. Introduction
Since 2012, the number of new opioid prescriptions in the United
States has steadily declined.4,11 However, between 2006 and
2017, the proportion of 30-day opioid prescriptions and the
average duration of prescriptions increased.26 This is a concern
because long-term opioid therapy (LTOT) is associated with
numerous adverse outcomes, including increased risk for
depression.9,22,25,34 Among patients with noncancer pain, and
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in multiple patient cohorts, LTOT (.90 days) compared with
short-term use (,30 days) is associated with an increased risk for
new-onset depression22,25 and development of treatmentresistant depression.24 These associations were independent of
pain and comorbid psychiatric disorders. Recently, Rosoff et al.
used a Mendelian randomization approach (in which genetic
predisposition to opioid use is used as an instrumental variable) to
demonstrate a possible causal link between opioid use and risk
for depression.18 However, not all patients receiving LTOT
develop depression, and further work is needed to determine
the characteristics of LTOT that are associated with risk for newonset depression.
Most existing literature in this field is based on retrospective cohort
designs, and 2 prospective cohort studies have failed to identify a
significant association between LTOT and new-onset depression or
worsening depression after controlling for confounding factors. In the
Pain and Opioids IN Treatment study,6 longer duration of opioid use
was not significantly associated with developing depression after
adjusting for duration of pain and comorbid psychiatric disorders.28
In a prospective cohort of patients starting LTOT for noncancer pain,
Von Korff et al.33 observed no difference in depression symptoms
between patients with regular, high-dose use compared with
intermittent, low-dose use.33 However, the authors suggest that
the low dose (,50 morphine milligram equivalent [MME]) among
regular and intermittent users diminished the chance of detecting
a difference in depression between regular and intermittent users.
We have observed that higher MME doses, specifically 51 to 100
MME and .100 MME vs 1 to 50 MME, were not associated
with risk for depression when controlling for duration of opioid use.22
This finding in the context of Von Korff et al.33 results leaves the
www.painjournalonline.com
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potential that intermittent use vs more frequent use is a key reason
long-term opioid use is associated with depression. However, there
are no studies that have evaluated the association between
frequency of use in LTOT and risk for new-onset depression.
It is possible that using opioids a few days a week, as
compared with daily, avoids opioid tolerance and dependence,
allowing opioid receptors to recover and perform their role in
generating hedonic capacity. Another possibility is that continuous LTOT leads to opioid dependence that is equivalent to the
withdrawal and negative affect stage of addiction. This stage is
preceded by a period in which euphoric, positive reward drives
use.3 Intermittent opioid users may experience less or no
psychological reward from opioids, whereas euphoria is likely
more common among frequent users. With more frequent use,
risk of physiological dependence increases, and patients will
experience negative affect that could worsen to clinically
meaningful depression.
If daily or near-daily opioid use impairs the ability to experience
pleasure and/or generates repeated short-term withdrawal/negative
affect, then daily compared with intermittent opioid use in patients
receiving LTOT should be associated with greater risk for new-onset
depression. This study compared patients with a new period of
.90-day prescription opioid use who used opioids occasionally,
intermittently, frequently, and daily. We hypothesized that increasing
opioid use frequency would be associated with escalating probability
of new-onset depression. We then determined if this association
remained after adjusting for pain diagnoses made after the start of
opioid use. We also assessed whether opioid use disorder
diagnoses after opioid initiation could be a possible mechanism
through which frequency of opioid use could affect the risk of newonset depression.

date (start of follow-up) was day 91 after the first 90 days of a new
opioid use period. This allowed for sampling patients with LTOT
(.90 days use). In the 1 year before the start of a new opioid use
period, we required a claim or encounter to identify current health
care users. Patients with cancer or HIV in the 1 year before start of
opioid use or in the first 90 days of LTOT were excluded. To
identify new prescription opioid use, we excluded patients with
any opioid prescription in the EHR or opioid fill in claims data in the
6 months before the start of new opioid use. The new period of
opioid use was limited to those starting a new period of .90 days
of continuous opioid use (ie, LTOT). Continuous opioid use was
measured using days supply, accounting for overlapping fills, and
allowing for no gap between fills .30 days. Once a gap of .30
days occurred, the new period of opioid use ended. Using the first
and last opioid fills in the new opioid use period, duration was
calculated as the difference in days between the last fill date and
the start date of the first fill. Opioid use frequency was calculated
within the first 90 days of the new LTOT period. Patients were
required to be free of depression diagnoses for 1 year before the
start of the new opioid use period and throughout the new 90-day
opioid use period. The index date was day 91 of the new LTOT.
This eligibility criteria led to excluding patients without health
insurance. All patients must have had one or more encounters or
claims after index date and had to be between 18 and 80 years of
age at start of the new period of opioid use. Patients with missing
demographic data were excluded (n 5 4 missing gender), leaving
5146 patients in the analytic sample. The sample selection
process is illustrated in Figure 1 and the retrospective cohort
design is visualized in e-Figure 1 (supplemental digital content,
http://links.lww.com/PAIN/B546).
2.1. Outcome variable

2. Methods
Saint Louis University provided funding to the author (J.F.S.) to
lease an Optum analytics database that contained de-identified
electronic health records (EHRs) from a random sample of 5
million adult ($18 years of age) patients. These patients had
medical encounters in health systems across the United States
between 2010 and 2018, and about 39% were from the Midwest,
14% from the Northeast, 27% from the South, and 11% from the
West. Of the 5 million patients, approximately 18% were part of
Optum’s de-identified Integrated Claims-Clinical dataset (n 5
897,513), which included data from EHR and medical claims. All
study variables were created from data elements in the integrated
EHR-claim files. The EHR and claims data includes outpatient
and inpatient encounters from academic and nonacademic
healthcare systems between 2010 and 2018. The data include
patients with private, government, or no health insurance.
International Classification of Diseases, Ninth Revision (ICD-9)
Clinical Modification and International Classification of Diseases,
Tenth Revision (ICD-10) Clinical Modification codes, pharmacy
claims, prescriptions, vital signs, laboratory results, demographics, and geographic region were used to create study variables.
We created a retrospective cohort of patients starting a new
period of opioid therapy by first requiring patients to have one or
more prescription opioid fills in 2011 to 2016. This allowed for a 1year look-back period and a minimum of 2-year follow-up for
onset of depression. The maximum possible follow-up was 7.75
years. Patients could enter the cohort at anytime during this
observation period once they met eligibility criteria. Patients
entered the cohort at the start of a new opioid use period meeting
eligibility and only the first eligible LTOT period was included in the
analysis (ie, patients only counted once in the analysis). The index

Detailed definitions for all variables are listed in e-table 1
(supplemental digital content, http://links.lww.com/PAIN/B546).
New-onset depression was defined by the presence of ICD-9
codes 296.2x, 296.3x, and 311 and ICD-10 codes F32.0-F32.5,
F32.9, F33.0-F33.3, F33.4x, and F33.9. A new case of depression was defined by ICD-9 and ICD-10 codes for depression
on 1 inpatient visit or 2 outpatient visits within the same 12 months
of follow-up. This diagnostic algorithm has excellent agreement
with chart abstraction and patient report.10,31

3. Exposure
The following prescription opioids, in both immediate- and
extended-release formulations, were used to measure opioid
use: codeine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine, methadone, morphine,
oxycodone, oxymorphone, pentazocine, tapentadol, and tramadol. Due to a lack of precision in linking buprenorphine to a pain
condition, we did not include it as an opioid exposure.
Buprenorphine is predominately prescribed for opioid use
disorder, and patients with problem opioid use are sometimes
switched from another opioid to buprenorphine. Following the
concept of Smolina et al.,29,30 we used the proportion of days that
an opioid supply was available in the first 90 days of use to create
categories for frequency of opioid use. We computed the
distribution of days covered in the first 90 days29,30 (e-table 2,
supplemental digital content, http://links.lww.com/PAIN/B546)
and the distribution of hazard ratios (HRs) for the risk of
depression for every 10% (9 day) increase in frequency of use
(e-table 3, supplemental digital content, http://links.lww.com/
PAIN/B546). Balancing confounding factors across 10

Copyright © 2022 by the International Association for the Study of Pain. Unauthorized reproduction of this article is prohibited.

August 2022

·

Volume 163

·

Number 8

www.painjournalonline.com

1583

period. Intermittent use was defined by 50% to ,80% days
covered, which equates to 45 to 71 days of opioid use. Frequent
use was defined as 80% to ,90% days covered, which equates
to 72 to 80 days of opioid use. Daily use was defined as $90%
days covered, which equates to $81 days of opioid use during
the first 90-day use period.
3.1. Follow-up time
Follow-up time was defined as months from index date to newonset depression or censoring. Among patients not developing
new-onset depression in follow-up, censoring was defined as the
last available claim or encounter. Follow-up time for these
patients was the difference in months from index to censor date.
So, for example, if index date was January 1, 2012 and a patient
was censored at April 20, 2012, follow-up time was 4 months. For
someone developing depression, follow-up time was calculated
similarly as the difference in months from index to new-onset
depression date.

3.2. Potential confounders

Figure 1. Sampling approach. EHR, electronic health record.

categories was not feasible; therefore, we used the distribution of
HRs to create 4 categories that permitted control for confounding. Compared with ,50% of days covered (,45 days), risk for
new-onset depression did not increase until 80% (72 days) of
days covered, with another increase at 90% (81 days). Thus,
occasional use was defined by ,50% days covered, which
equates to ,45 days of opioid use during the first 90-day use

We selected potential confounding factors that theoretically could
be associated with opioid prescribing or with risk for depression
and based on our previous studies of prescription opioid use and
new-onset depression.22 Covariates included demographics,
geographic region, health care use, maximum MME dose, and
comorbid physical and psychiatric conditions. See e-table 1 for
detailed variable definitions (supplemental digital content, http://
links.lww.com/PAIN/B546).
Demographic variables included age, gender, and race.
Census-based geographic regions were defined as Midwest,
Northeast, South, West, and Other/unknown. To control for
detection bias, we computed the distribution of the mean number
of clinical encounters per month. The top 25th percentile was
defined as high utilization.
Maximum MME achieved during the first 90 days of opioid use
was calculated using standard equianalgesic conversion tables.
We assumed patients took the maximum dose prescribed per
day based on days supply and quantity dispensed. MME was
classified into 1 to 50, 51 to 90, 91 to 180, and .180 mg.
Following the approach used in previous studies of opioid use
and depression,19,21–24 we created separate variables for pain
conditions derived from .900 conditions for which an opioid may
be prescribed.27 Pain conditions were arthritis, back pain,
musculoskeletal pain, neuropathy, and headache. ICD-9 and
ICD-10 codes were used to define type 2 diabetes, ischemic
heart disease, stroke, low testosterone, and sleep apnea. Obesity
was defined by ICD-9/10 diagnostic code or body mass index of
$30 kg/m2.
ICD-9 and ICD-10 codes were used to measure psychiatric
covariates, including alcohol abuse/dependence, any form of
drug abuse/dependence, including opioid abuse/dependence
and nicotine dependence, and any anxiety disorder, and
prescription data were used to measure benzodiazepine comedication. Any anxiety disorder was a diagnosis for posttraumatic stress disorder, panic disorder, obsessive compulsive
disorder, social phobia, generalized anxiety disorder, or anxiety
not otherwise specified. Benzodiazepine co-medication was
defined as a prescription or fill for any benzodiazepine that
overlapped with the first 90 days of the new LTOT period. Pain,
physical and psychiatric comorbidities were measured from
January 1, 2010 to index date.

Copyright © 2022 by the International Association for the Study of Pain. Unauthorized reproduction of this article is prohibited.

1584

·

PAIN®

J.F. Scherrer et al. 163 (2022) 1581–1589

3.3. Analytic approach
All primary analyses were performed with SAS v9.4 (SAS Institute,
Cary, NC) at a 2-tailed alpha 5 0.05. Distributions of variables are
presented as mean values (6SD) or frequency and percent.
3.3.1. Weighting
Bias by indication may confound the association between
frequency of opioid use and new-onset depression. Thus, we
balanced all potential confounders across categories of frequency of opioid use using propensity scores (PS) and inverse
probability of exposure weighting (IPEW). Successful balancing of
covariates allows for unbiased estimates of exposure effects.7,17
Propensity scores were calculated using generalized boosted
modeling.14,15 Generalized boosted modeling often outperforms
traditional regression techniques for PS analysis (eg, logistic,
multinomial), especially with multiple exposure groups. Generalized boosted modeling is a nonparametric, iterative regression
technique that assesses and incorporates multiple interaction
and higher order terms, which reduces the risk of model
misspecification, and allows for deviations in additivity and
linearity. Generalized boosted modeling estimation of the PS for
multiple exposure groups was conducted using the “twang”
package in R v4.0.3.5
After obtaining PS scores, stabilized weights (observed
exposure probability 3 1/PS) were calculated to retain original
sample size in weighted analysis and reduce bias associated with
extreme weights (large variance).35 Standardized mean difference percent, a common effect size measure (SMD% 5 100 3
SMD), assessed covariate balance between frequency groups,
with a threshold of $10% defining imbalance.2 The SMD
compares differences in mean values in units of SD. Although
originally created for comparing continuous variables, it has been
shown that it can be used for binary/dichotomous variables.1
Because there are 4 exposure categories, the maximum SMD%
of all pairwise comparisons was reported. Also, for multicategory
confounders (race, region, and maximum daily MME), a binary
indicator was created for each level and SMD% for each level was
calculated. Standardized mean difference % formulas are shown
in e-Table 4 (supplemental digital content, http://links.lww.com/
PAIN/B546).
3.3.2. Primary analysis
Bivariate comparisons between covariates and opioid use
frequency group were performed using x2 tests for categorical
variables and 1-way analysis of variance for continuous variables.
Standardized mean difference % before and after weighting
assessed covariate balance. Cox proportional hazard models
before and after weighting were used to calculate HRs and 95%
confidence intervals (CIs) for the association between frequency
of opioid use and new-onset depression. Weighted models used
robust, sandwich-type variance estimators for CIs and P-values.2
The proportional hazard assumption was tested in unweighted
and weighted models by including a time-dependent interaction
term of opioid use frequency and log (follow-up time); the
assumption was met for all models (P . 0.05).
The e-value for the HR point estimates was calculated to
determine if unmeasured confounding could explain significant
results.12 The e-value is the minimum strength of association (for
this analysis, the minimum HR) needed for any unmeasured
confounder to have with both the exposure and the outcome to
completely explain observed associations. Because there were 4

exposure groups, the minimum calculated e-value for any
significant pairwise point estimate was given.
3.3.3. Secondary analyses
To determine whether pain conditions that could occur after index
and before new-onset depression (or censoring) could explain the
relationship between frequency of opioid use and new-onset
depression, we extended the weighted Cox model by adding
time-dependent pain covariates in follow-up. More frequent
opioid use may increase risk for opioid use disorder that may
subsequently lead to depression. Thus, a separate extended
weighted model was calculated that included a time-dependent
indicator for opioid use disorder in follow-up.

4. Results
As shown in Table 1, the cohort was on average 54.5 (SD 6 13.6)
years of age, 55.7% were female, 72.5% were White, and 9.5%
were African American. Most patients were from the Midwest or
Southern United States. Most patients had a maximum MME
#90 mg. Back pain, arthritis, and musculoskeletal pain were the
most common pain conditions. Alcohol and drug abuse/
dependence were present in ,7% of the sample and nearly
one-third had nicotine dependence. Approximately 15% had a
diagnosis for an anxiety disorder and 23.8% had a benzodiazepine co-medication.
The covariate distributions by categories of opioid use
frequency are shown in Table 2. Patients with maximum MME
of 1 to 50 mg were most common among intermittent users (SMD
% 5 36.6) and those with maximum MME of 51 to 90 mg were
more prevalent among occasional users (SMD% 5 18.9). There
were more patients with 91 to 180 MME in the frequent and daily
user groups (SMD% 5 10.2). The prevalence of patients with a
maximum MME .180 mg increased with each category of more
frequent opioid use (SMD% 5 45.0).
Arthritis was least prevalent, whereas back pain was most
prevalent among daily users (SMD% 5 15.2 and 22.3, respectively). Musculoskeletal pain was most common among
occasional users (SMD% 5 32.6), and headache was most
common among occasional and intermittent users (SMD% 5
12.4%). The prevalence of drug abuse/dependence increased
with each category of more frequent opioid use (SMD% 5
21.8%). Benzodiazepine co-medication was most prevalent
among daily users (SMD% 5 17.2).
Median follow-up time was 32 months (interquartile range [IQR]
5 16-55). Median follow-up time by opioid use frequency group
was: (1) occasional 5 40 months (IQR 5 21-64); (2) intermittent 5
36 months (IQR 5 19-57); (3) frequent 5 33 months (IQR 5 1655); and (4) daily 5 30 months (IQR 5 15-50). Among patients
who developed depression, median follow-up time was 15
months (IQR 5 6-28).
The median follow-up time to depression was 18 months (IQR
5 5-34) among occasional users, 14 months (IQR 5 6-30) among
intermittent users, 16 months (IQR 5 7-27) among frequent
users, and 15 months (IQR 5 6-26) among daily users.
Among the entire sample, 26.7% developed depression in
follow-up. The overall unadjusted incidence rate of new-onset
depression per 1000 person-years (PY) was 88.7/1,000 PY. The
new-onset depression incidence rate increased from 68.1/1,000
PY among occasional users to 69.9/1,000 PY among intermittent
users to 93.7/1000 PY for frequent users to 110.0/1000 PY
among daily users (Table 3).
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Table 1

Demographic and baseline characteristics (%) of new longterm prescription opioid users aged 18 to 80 years (n 5 5146).
Covariates, n (%) or mean (6SD)

Overall (n 5 5146)

Sociodemographic related
Age, mean (6SD), y
Female gender
Race
White
Black
Other/unknown
Region
Midwest
Northeast
South
West
Other/unknown
High healthcare utilization

1639 (31.8)
498 (9.7)
2262 (44.0)
559 (10.9)
188 (3.6)
1287 (25.0)

Opioid related
Maximum daily MME (mg)*
1-50
51-90
91-180
.180

2491 (48.4)
1264 (24.6)
853 (16.6)
538 (10.4)

Comorbidities†
Arthritis
Back pain
Muscle pain
Neuropathy
Headache
Type II diabetes
Obesity
Ischemic heart disease
Stroke
Low testosterone
Sleep apnea
Alcohol abuse/dependence
Drug abuse/dependence
Nicotine dependence
Any anxiety disorder‡
Benzodiazepine co-medication§

3426 (66.6)
3629 (70.5)
3335 (64.8)
1046 (20.3)
1129 (21.9)
1323 (25.7)
1502 (29.2)
861 (16.7)
168 (3.3)
190 (3.7)
604 (11.7)
173 (3.4)
336 (6.5)
1521 (29.6)
781 (15.2)
1226 (23.8)

54.5 (613.6)
2869 (55.7)
3732 (72.5)
488 (9.5)
926 (18.0)

* MME—measured in first 90 days of new long-term opioid use (opioid start to index date).
† Comorbidities measured from start of data (January 1, 2010) to index date.
‡ Anxiety disorders 5 posttraumatic stress disorder, panic disorder, obsessive compulsive disorder, social
phobia, generalized anxiety disorder, anxiety not otherwise specified.
§ Benzodiazepine co-med 5 fill or prescription during the first 90 days of new long-term opioid use (opioid
start to index date).
MME, morphine milligram equivalent.

Results in e-Table 5 show SMD% estimates for each covariate
after IPEW, which weights analyses using stabilized weights, to
assess balance between groups. As shown in the supplementary
e-Table 5 (supplemental digital content, http://links.lww.com/
PAIN/B546), IPEW balanced all baseline covariates across opioid
use frequency groups (all maximum pairwise SMD% ,10%). The
stabilized weights obtained from PS models ranged from 0.31 to
4.73, with a mean 5 0.99 (SD 6 0.34) (results not shown).
Cox proportional hazard models estimating the association
between frequency of opioid use and new-onset depression are
shown in Table 4. After controlling for confounding by using
weighted data (see model 2), we observed daily prescription
opioid use compared with occasional use was associated with
increased risk for new-onset depression (HR 5 1.40; 95% CI:
1.14-1.73). Frequent use compared with occasional use was
significantly associated with increased risk for new-onset depression (HR 5 1.34; 95% CI: 1.05-1.71). The risk for new-onset
depression did not differ between intermittent compared with

1585

occasional users. After extending the model by allowing for pain
conditions that could occur after 90 days of opioid use, there
were only small changes in the associations between frequency
of opioid use and new-onset depression (see model 3). There was
little change in the association between frequency of prescription
opioid use and new-onset depression after accounting for the
contribution of opioid use disorder that could occur after 90 days
of opioid use (see model 4). Among the entire sample, 8.3% had
opioid use disorder after 90 days of opioid use, and the
prevalence of opioid use disorder increased with each category
of opioid duration (P , 0.0001): occasional, 3.1%; intermittent,
5.3%; frequent, 8.3%; and daily, 11.9%.
As shown in the footnote to Table 4, post-hoc comparisons
between each category of opioid use duration revealed a
significantly greater risk for depression in daily users vs
intermittent users (HR 5 1.40; 95% CI: 1.23-1.61) and in frequent
vs intermittent users (HR 5 1.35; 95% CI: 1.12-1.61). There was
no significant difference in depression risk between daily and
frequent users. These comparisons remained largely unchanged
after extending models by adding post 90-day opioid use pain
conditions or opioid abuse/dependence.
The minimum e-value for any significant pairwise HR comparison in the weighted model was 1.58. A covariate would need at
least this association with both the exposure and the outcome to
completely explain significant findings.

5. Discussion
In a large, nationally distributed cohort of patients with LTOT, we
observed that increasing frequency of prescription opioid use is
associated with greater risk for new-onset depression. In patients
with .90-day opioid use, daily users and frequent users,
compared with intermittent users, had a 40% and a 34%
increased risk, respectively, for new depression episodes. This
association was independent of maximum daily MME, pain
conditions, comorbid psychiatric disorders, physical conditions,
benzodiazepine co-medication, and demographics. The relationship between greater frequency of opioid use and new-onset
depression remained significant after accounting for the contribution of pain diagnoses and opioid use disorder that could occur
after the new 90-day opioid use period and before depression
onset.
There was evidence of a threshold for risk because patients who
used an opioid $90% (ie, daily) and those who used $80% (ie,
frequently) did not differ in risk for depression. Those who used
50% to ,80% of the time did not differ in risk from those who used
,50% of the time. Therefore, the prior evidence that .90-day
prescription opioid use is associated with new-onset depression22,25 is possibly due to the subgroup of LTOT who use daily or
near daily. In addition, this finding supports the concept that nearly
continuously occupied opioid receptors may prevent normal
hedonic capacity leading to anhedonia and/or depression.3,8,13
Some have suggested that depression develops in frequent LTOT
because of the negative affect associated with withdrawal.16 Our
results do not directly address this issue but we observed that
opioid use disorder after 90 days of opioid use did not modify the
association between more frequent opioid use and new-onset
depression. To the degree that opioid use disorder is diagnosed by
providers, this finding suggests that opioid use disorder does not
explain the relationship between frequent LTOT and new-onset
depression. It is also possible that intermittent users were able to
limit their opioid use because they had better overall mental health.
Symptoms of depression, not reaching criteria for a diagnosis, may
have been lower in those with intermittent use and that could

Copyright © 2022 by the International Association for the Study of Pain. Unauthorized reproduction of this article is prohibited.

1586

·

PAIN®

J.F. Scherrer et al. 163 (2022) 1581–1589

Table 2

Demographic and baseline characteristics by prescription opioid use frequency* (n 5 5146).
Occasional (n 5 582)

Intermittent (n 5 1661)

Frequent (n 5 664)

Daily (n 5 2239)

P

Max SMD%†

Age, mean (6SD), y

52.8 (613.8)

55.2 (614.1)

53.7 (614.0)

54.7 (613.0)

0.001

17.5

Female gender

344 (59.1)

935 (56.3)

359 (54.1)

1231 (55.0)

0.245

10.2

Race
White
Black
Other/unknown

434 (74.6)
45 (7.7)
103 (17.7)

1205 (72.6)
147 (8.8)
309 (18.6)

484 (72.9)
60 (9.0)
120 (18.1)

1609 (71.9)
236 (10.5)
394 (17.6)

0.378

6.1
9.8
2.6

Region
Midwest
Northeast
South
West
Other/unknown
High healthcare utilization

210 (36.1)
60 (10.3)
223 (38.3)
57 (9.8)
32 (5.5)
158 (27.2)

532 (32.0)
180 (10.8)
715 (43.1)
182 (11.0)
52 (3.1)
432 (26.0)

197 (29.7)
63 (9.5)
300 (45.2)
76 (11.5)
28 (4.2)
158 (23.8)

700 (31.3)
195 (8.7)
1024 (45.7)
244 (10.9)
76 (3.4)
539 (24.1)

Maximum daily MME (mg)
1-50
51-90
91-180
.180

293 (50.3)
178 (30.6)
89 (15.3)
22 (3.8)

961 (57.9)
384 (23.1)
239 (14.4)
77 (4.6)

344 (51.8)
148 (22.3)
119 (17.9)
53 (8.0)

893 (39.9)
554 (24.7)
406 (18.1)
386 (17.2)

Arthritis

405 (69.6)

1164 (70.1)

448 (67.5)

1409 (62.9)

,0.0001

15.2

Back pain

363 (62.4)

1160 (69.8)

477 (71.8)

1629 (72.8)

,0.0001

22.3

Covariates, n (%) or mean (6SD)

0.020

0.276

,0.0001

13.7
7.2
15.1
5.4
11.7
7.7
36.6
18.9
10.2
45.0

Muscle pain

434 (74.6)

1148 (69.1)

422 (63.6)

1331 (59.5)

,0.0001

32.6

Neuropathy

117 (20.1)

355 (21.4)

146 (22.0)

428 (19.1)

0.231

7.1

Headache

135 (23.2)

413 (24.9)

131 (19.7)

450 (20.1)

0.002

12.4

Type II diabetes

129 (22.2)

433 (26.1)

169 (25.5)

592 (26.4)

0.204

10.0

Obesity

169 (29.0)

520 (31.3)

204 (30.7)

609 (27.2)

0.034

9.0

Ischemic heart disease

97 (16.7)

288 (17.3)

123 (18.5)

353 (15.8)

0.325

7.3

Stroke

15 (2.6)

66 (4.0)

16 (2.4)

71 (3.2)

0.164

8.9

Low testosterone

15 (2.6)

64 (3.9)

18 (2.7)

93 (4.2)

0.152

8.8

Sleep apnea

83 (14.3)

198 (11.9)

83 (12.5)

240 (10.7)

0.100

10.7

Alcohol abuse/dependence

30 (5.2)

53 (3.2)

22 (3.3)

68 (3.0)

0.084

10.7

Drug abuse/dependence

21 (3.6)

71 (4.3)

46 (6.9)

198 (8.8)

,0.0001

21.8

Nicotine dependence

184 (31.6)

483 (29.1)

188 (28.3)

666 (29.8)

0.594

7.2

Any anxiety disorder

93 (16.0)

246 (14.8)

91 (13.7)

351 (15.7)

0.569

6.4

Benzodiazepine co-medication

117 (20.1)

339 (20.4)

157 (23.6)

613 (27.4)

,0.0001

17.2

* Occasional use 5 ,50% days covered/,45 days of opioid use during the first 90-day use period. Intermittent use 5 50% to ,80% days covered/45 to 71 days of opioid use during the first 90-day use period. Frequent use
5 80% to ,90% of days covered/72 to 80 days of opioid use during the first 90-day use period. Daily use 5 $90% days covered/$81 days of opioid use during the first 90-day use period.
† Maximum SMD percent (SMD% 5 100 3 SMD) of all group pairwise comparisons.
MME, morphine milligram equivalent; SMD, standardized mean difference.

reduce the number of new-onset depression diagnoses in those
who used less often.
Another explanation for our results could be development of
hyperalgesia and negative reward in more frequent users.13,15 As
initial euphoria associated with opioid use is replaced by
increased pain sensitivity and acute withdrawal, negative reward
may contribute to more frequent use and low mood. Another
mechanism could be opioid-induced testosterone deficiency,
which has been associated with LTOT and depression.6 Yet, our
results remained after controlling for low testosterone. In addition
to more frequent use leading to opioid dependence and
withdrawal and subsequent worsening of negative affect, LTOT
in humans has been associated with changes in brain regions (ie,
nucleus accumbens and amygdala) involved in motivation,
reward, and mood regulation.32,36 These changes last long after
opioid cessation.36 We speculate that frequent LTOT limits the

brain’s ability to generate natural reward and maintain normal
hedonic tone, leading to low mood and depression.
Our results are inconsistent with 2 prospective cohort studies.
The Pain and Opioids IN Treatment study reported that the
association between opioid use and risk for depression was
largely explained by comorbid psychiatric disorders and duration
of pain.28 While we lacked measures on the duration of pain
conditions, we used robust methods to control for acute and
chronic pain diagnoses before and after the 90-day opioid use
exposure. As shown in several previous studies, controlling for
psychiatric disorders, including substance use disorder, and
opioid abuse/dependence did not change the association
between LTOT and new-onset depression.22,25 In a separate
study, Von Korff et al.33 suggested that a lack of increase in
depression symptoms with long-term opioid use could be due to
older study participants not exceeding ,50 MME. Higher MME
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Table 3

New onset depression events—cumulative incidence % and incidence rate per 10,000 person-years.
Group

Total n

NOD events

Cumulative incidence %

Incidence rate per 1000 PY

Overall

5146

1376

26.7

88.7/1000 PY

Opioid use intensity*
Occasional
Intermittent
Frequent
Daily

582
1661
664
2239

135
372
189
680

23.2
22.4
28.5
30.4

68.1/1000 PY
69.9/1000 PY
93.7/1000 PY
110.0/1000 PY

* Occasional use 5 ,50% days covered/,45 days of opioid use during the first 90-day use period. Intermittent use 5 50% to ,80% days covered/45 to 71 days of opioid use during the first 90-day use period. Frequent use
5 80% to ,90% of days covered/72 to 80 days of opioid use during the first 90-day use period. Daily use 5 $90% days covered/$81 days of opioid use during the first 90-day use period.
NOD, new-onset depression; PY, person-years.

was positively correlated with more frequent opioid use in our
study. However, we balanced the difference in MME across
opioid use frequency groups, which suggests that our findings
are not explained by opioid dose. Nonetheless, we have found
that rapid increases in MME vs stable MME are associated with
new-onset depression.19 Therefore, we computed post-hoc
analysis to compare the difference in daily MME between the first
and last dose in the 90-day opioid use period. Occasional and
intermittent users had no significant change in dose (41.2 MME to
40.7 MME and 36.4 MME to 37.9 MME, respectively). Frequent
and daily users had significant dose increases (41.5 MME to 46.1
MME and 64.7 MME to 77.8 MME, respectively). It is possible that
rapid increases in dose is a contributing factor to the association
between more frequent use and new-onset depression.
Future research is needed to model the risk of depression using
variables that are measured prospectively and map onto the
measures applied in retrospective cohort studies that demonstrate
a strong association between duration and intensity of prescription
opioid use and risk for depression. We are currently collecting data in
such a prospective design20 to establish if there is a causal
association between frequent prescription opioid use and newonset depression among patients receiving LTOT.

5.1. Limitations
We did not have data on whether patients used their prescription
opioid. We lacked data to identify pro re nata (PRN) opioid
prescriptions. It is possible that PRN prescriptions were more
common among intermittent users, and future studies should
investigate risk for new-onset depression in patients with PRN vs
opioid prescriptions written for daily use. The relatively large
percent of patients with unknown race limited conclusions about
differences by race within those classified as unknown. Uninsured patients did not meet eligibility criteria and results may not
generalize to this patient group. Misclassification is a risk. Even
though our depression algorithm has been validated, there is
chance that we misclassified some patients as nondepressed
when they actually had undiagnosed depression. This would tend
to bias our estimates to the null, and our point estimates could be
conservative. Unmeasured confounding is a potential limitation.
Based on our e-value, an unmeasured confounder would have to
have a HR of 1.58 with both opioid use frequency and new-onset
depression to completely explain our results.12 We are unable to
conceive of such a variable. For instance, our previous studies of
LTOT and depression revealed that greater pain severity scores
were associated with only a 24% increased risk for depression.22

Table 4

Results from Cox proportional hazard models estimating the association of prescription opioid use frequency and new-onset
depression (n 5 5146)*.
Opioid use intensity†

Model 1—crude/
unweighted

Model
2—weighted‡

Model 3—weighted 1 time-dependent
post-index pain§

Model 4—weighted 1 time-dependent
post-index OUD‖

HR (95% CI)

HR (95% CI)

HR (95% CI)

HR (95% CI)

Occasional

1.00

1.00

1.00

1.00

Intermittent

1.01 (0.83-1.22)

1.00 (0.80-1.24)

0.98 (0.78-1.22)

0.98 (0.79-1.23)

Frequent

1.33 (1.07-1.66)

1.34 (1.05-1.71)

1.29 (1.01-1.64)

1.31 (1.03-1.67)

Daily

1.52 (1.26-1.82)

1.40 (1.14-1.73)

1.32 (1.07-1.63)

1.35 (1.09-1.67)

Arthritis

1.17 (1.03-1.33)

Back pain

1.20 (1.06-1.36)

Muscle pain

1.15 (1.01-1.32)

Neuropathy

1.34 (1.16-1.55)

Headache

1.42 (1.23-1.64)

Opioid abuse/
dependence

1.95 (1.54-2.47)

Weighted models use propensity scores and inverse probability of exposure weighting to control for confounders by balancing confounder distributions between exposure groups.
* P-values for test of proportional hazards assumption: unweighted (P 5 0.99); weighted (P 5 0.92)—all P . 0.05, therefore assumption is met for models.
† Occasional use 5 ,50% days covered/,45 days of opioid use during the first 90-day use period. Intermittent use 5 50% to ,80% days covered/45 to 71 days of opioid use during the first 90-day use period. Frequent use
5 80% to ,90% of days covered/72 to 80 days of opioid use during the first 90-day use period. Daily use 5 $90% days covered/$81 days of opioid use during the first 90-day use period.
‡ Other weighted comparisons (model 2): frequent vs intermittent, HR 5 1.35 (1.12-1.61); daily vs intermittent, HR 5 1.40 (1.23-1.61); daily vs frequent, HR 5 1.04 (0.88-1.23).
§ Other weighted comparisons (model 3): frequent vs intermittent, HR 5 1.31 (1.10-1.58); daily vs intermittent, HR 5 1.35 (1.18-1.55); daily vs frequent, HR 5 1.03 (0.87-1.22).
‖ Other weighted comparisons (model 4): frequent vs intermittent, HR 5 1.33 (1.12-1.60); daily vs intermittent, HR 5 1.37 (1.20-1.57); daily vs frequent, HR 5 1.03 (0.87-1.22).
CI, confidence interval; HR, hazard ratio; OUD, opioid use disorder.
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We did not have pain scores in our data. However, our previous
studies in Veteran Health Administration cohorts indicate that the
association between LTOT and new-onset depression is independent of pain score severity.21,23 Finally, we do not have
adequate measurement of lifetime measures of depression; the
association between more frequent opioid use and new-onset
depression may be more common in patients who had a lifetime
history of depression that preceded our observation period.
However, there were only 47 patients with a new-onset
depression episode defined by diagnostic codes for recurring
depression. Because these patients could have had a depressive
episode before our observation period, we conducted post-hoc
sensitivity analysis by excluding these patients and results
remained unchanged.

[3]
[4]

[5]

[6]

[7]

6. Conclusions

[8]

In a cohort of EHR data with integrated claims data, patients
receiving LTOT had an increased risk for depression if they are
using an opioid at least 80% of the time. There is no increased risk
for new-onset depression in patients with LTOT who use opioids
less frequently. The association may be explained by continual
occupation of opioid receptors that blocks natural reward
processes. Longitudinal cohort studies are needed to confirm
the mechanisms behind LTOT and increased risk for new-onset
depression. Clinicians need to repeatedly screen for depression
in patients receiving LTOT who are daily or near-daily users and
encourage nonpharmacological pain management for this
patient population.
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